IP Library › Patent Application 18273078

Patent Application

App. No. 18/273,078

ANTI-MET ANTIBODIES AND USES THEREOF

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US None
App. No.: 18/273,078

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

Provided herein are antibodies and uses of the same.

Claims (210)

1 .- 74 . (canceled)

75 . Nucleic acid comprising sequences encoding an antibody, wherein the antibody comprises:

(a) a heavy chain variable domain and a light chain variable domain selected from the group of:

(i) SEQ ID NO: 5 and SEQ ID NO: 6, respectively;

(ii) SEQ ID NO: 7 and SEQ ID NO: 8, respectively;

(iii) SEQ ID NO: 9 and SEQ ID NO: 10, respectively;

(iv) SEQ ID NO: 11 and SEQ ID NO: 12, respectively;

(v) SEQ ID NO: 13 and SEQ ID NO: 14, respectively;

(vi) SEQ ID NO: 15 and SEQ ID NO: 16, respectively;

(vii) SEQ ID NO: 17 and SEQ ID NO: 18, respectively;

(viii) SEQ ID NO: 19 and SEQ ID NO: 20, respectively;

(ix) SEQ ID NO: 21 and SEQ ID NO: 22, respectively;

(x) SEQ ID NO: 23 and SEQ ID NO: 24, respectively;

(xi) SEQ ID NO: 25 and SEQ ID NO: 26, respectively;

(xii) SEQ ID NO: 27 and SEQ ID NO: 28, respectively;

(xiii) SEQ ID NO: 29 and SEQ ID NO: 30, respectively;

(xiv) SEQ ID NO: 31 and SEQ ID NO: 32, respectively;

(xv) SEQ ID NO: 33 and SEQ ID NO: 34, respectively; and

(b) a heavy chain CH1-CH2-CH3 sequence of SEQ ID NO: 155 or SEQ ID NO: 189 comprising one or more of the following:

a lysine to cysteine substitution at amino acid position 105 and deletion of a threonine at amino acid positions 106 and 108;

a methionine to tyrosine substitution at amino acid position 135, a serine to threonine substitution at amino acid position 137, and a threonine to glutamic acid substitution at amino acid position 139;

a methionine to leucine substitution at amino acid position 311 and an asparagine to serine substitution at amino acid position 317; and

an alanine to a cysteine substitution at amino acid position 1; and/or

a light chain C L sequence of SEQ ID NO: 157 comprising a lysine to cysteine substitution at amino acid position 98.

76 . The nucleic acid of claim 75 , wherein the antibody comprises the heavy chain CH1-CH2-CH3 sequence of SEQ ID NO: 155 or SEQ ID NO: 189 comprising a lysine to cysteine substitution at amino acid position 105 and deletion of a threonine at amino acid positions 106 and 108.

77 . The nucleic acid of claim 76 , wherein the antibody comprises heavy chain and light chain sequences selected from the group of:

(i) SEQ ID NO: 35 and either SEQ ID NO: 41 or SEQ ID NO: 42, respectively;

(ii) SEQ ID NO: 43 and either SEQ ID NO: 49 or SEQ ID NO: 50, respectively;

(iii) SEQ ID NO: 51 and either SEQ ID NO: 57 or SEQ ID NO: 58, respectively

(iv) SEQ ID NO: 59 and either SEQ ID NO: 65 or SEQ ID NO: 66, respectively;

(v) SEQ ID NO: 67 and either SEQ ID NO: 73 or SEQ ID NO: 74, respectively;

(vi) SEQ ID NO: 75 and either SEQ ID NO: 81 or SEQ ID NO: 82, respectively;

(vii) SEQ ID NO: 83 and either SEQ ID NO: 89 or SEQ ID NO: 90, respectively;

(viii) SEQ ID NO: 91 and either SEQ ID NO: 97 or SEQ ID NO: 98, respectively;

(ix) SEQ ID NO: 99 and either SEQ ID NO: 105 or SEQ ID NO: 106, respectively;

(x) SEQ ID NO: 107 and either SEQ ID NO: 113 or SEQ ID NO: 114, respectively;

(xi) SEQ ID NO: 115 and either SEQ ID NO: 121 or SEQ ID NO: 122, respectively;

(xii) SEQ ID NO: 123 and either SEQ ID NO: 129 or SEQ ID NO: 130, respectively;

(xiii) SEQ ID NO: 131 and either SEQ ID NO: 137 or SEQ ID NO: 138, respectively;

(xiv) SEQ ID NO: 139 and either SEQ ID NO: 145 or SEQ ID NO: 146, respectively; and

(xv) SEQ ID NO: 147 and either SEQ ID NO: 153 or SEQ ID NO: 154, respectively.

78 . The nucleic acid of claim 77 , wherein the heavy and light chain sequences comprise SEQ ID NO: 75 and SEQ ID NO: 81, respectively.

79 . The nucleic acid of claim 78 , wherein the heavy and light chain sequences comprise SEQ ID NO: 75 and SEQ ID NO: 82, respectively.

80 . The nucleic acid of claim 79 , wherein the antibody comprises the light chain C L sequence of SEQ ID NO: 157 comprising a lysine to cysteine substitution at amino acid position 98.

81 . The nucleic acid of claim 75 , wherein the antibody comprises the heavy chain CH1-CH2-CH3 sequence of SEQ ID NO: 155 or SEQ ID NO: 189 comprising a lysine to cysteine substitution at amino acid position 105 and deletion of a threonine at amino acid positions 106 and 108; and a methionine to leucine substitution at amino acid position 311 and an asparagine to serine substitution at amino acid position 317.

82 . The nucleic acid of claim 81 , wherein the antibody comprises heavy chain and light chain sequences selected from the group of:

(i) SEQ ID NO: 36 and either SEQ ID NO: 41 or SEQ ID NO: 42, respectively;

(ii) SEQ ID NO: 44 and either SEQ ID NO: 49 or SEQ ID NO: 50, respectively;

(iii) SEQ ID NO: 52 and either SEQ ID NO: 57 or SEQ ID NO: 58, respectively;

(iv) SEQ ID NO: 60 and either SEQ ID NO: 65 or SEQ ID NO: 66, respectively;

(v) SEQ ID NO: 68 and either SEQ ID NO: 73 or SEQ ID NO: 74, respectively;

(vi) SEQ ID NO: 76 and either SEQ ID NO: 81 or SEQ ID NO: 82, respectively;

(vii) SEQ ID NO: 84 and either SEQ ID NO: 89 or SEQ ID NO: 90, respectively;

(viii) SEQ ID NO: 92 and either SEQ ID NO: 97 or SEQ ID NO: 98, respectively;

(ix) SEQ ID NO: 100 and either SEQ ID NO: 105 or SEQ ID NO: 106, respectively;

(x) SEQ ID NO: 108 and either SEQ ID NO: 113 or SEQ ID NO: 114, respectively;

(xi) SEQ ID NO: 116 and either SEQ ID NO: 121 or SEQ ID NO: 122, respectively;

(xii) SEQ ID NO: 124 and either SEQ ID NO: 129 or SEQ ID NO: 130, respectively;

(xiii) SEQ ID NO: 132 and either SEQ ID NO: 137 or SEQ ID NO: 138, respectively;

(xiv) SEQ ID NO: 140 and either SEQ ID NO: 145 or SEQ ID NO: 146, respectively; and

(xv) SEQ ID NO: 148 and either SEQ ID NO: 153 or SEQ ID NO: 154, respectively.

83 . The nucleic acid of claim 75 , wherein the heavy chain CH1-CH2-CH3 sequence of SEQ ID NO: 155 or SEQ ID NO: 189 comprises:

a lysine to cysteine substitution at amino acid position 105 and deletion of a threonine at amino acid positions 106 and 108; and

84 . The nucleic acid of claim 83 , wherein the antibody comprises heavy chain and light chain sequences selected from the group of:

(i) SEQ ID NO: 37 and either SEQ ID NO: 41 or SEQ ID NO: 42, respectively;

(ii) SEQ ID NO: 45 and either SEQ ID NO: 49 or SEQ ID NO: 50, respectively;

(iii) SEQ ID NO: 53 and either SEQ ID NO: 57 or SEQ ID NO: 58, respectively;

(iv) SEQ ID NO: 61 and either SEQ ID NO: 65 or SEQ ID NO: 66, respectively;

(v) SEQ ID NO: 69 and either SEQ ID NO: 73 or SEQ ID NO: 74, respectively;

(vi) SEQ ID NO: 77 and either SEQ ID NO: 81 or SEQ ID NO: 82, respectively;

(vii) SEQ ID NO: 85 and either SEQ ID NO: 89 or SEQ ID NO: 90, respectively;

(viii) SEQ ID NO: 93 and either SEQ ID NO: 97 or SEQ ID NO: 98, respectively;

(ix) SEQ ID NO: 101 and either SEQ ID NO: 105 or SEQ ID NO: 106, respectively;

(x) SEQ ID NO: 109 and either SEQ ID NO: 113 or SEQ ID NO: 114, respectively;

(xi) SEQ ID NO: 117 and either SEQ ID NO: 121 or SEQ ID NO: 122, respectively;

(xii) SEQ ID NO: 125 and either SEQ ID NO: 129 or SEQ ID NO: 130, respectively;

(xiii) SEQ ID NO: 133 and either SEQ ID NO: 137 or SEQ ID NO: 138, respectively;

(xiv) SEQ ID NO: 141 and either SEQ ID NO: 145 or SEQ ID NO: 146, respectively; and

(xv) SEQ ID NO: 149 and either SEQ ID NO: 153 or SEQ ID NO: 154, respectively.

85 . The nucleic acid of claim 75 , wherein:

the heavy chain CH1-CH2-CH3 sequence of SEQ ID NO: 155 or SEQ ID NO: 189 comprises a lysine to cysteine substitution at amino acid position 105 and deletion of a threonine at amino acid positions 106 and 108; and

the light chain C L sequence of SEQ ID NO: 157 comprises a valine to cysteine substitution at amino acid position 98.

86 . The nucleic acid of claim 85 , wherein the antibody comprises heavy chain and light chain sequences selected from the group of:

(i) SEQ ID NO: 35 and SEQ ID NO: 42, respectively;

(ii) SEQ ID NO: 43 and SEQ ID NO: 50, respectively;

(iii) SEQ ID NO: 51 and SEQ ID NO: 58, respectively;

(iv) SEQ ID NO: 59 and SEQ ID NO: 66, respectively;

(v) SEQ ID NO: 67 and SEQ ID NO: 74, respectively;

(vi) SEQ ID NO: 75 and SEQ ID NO: 82, respectively;

(vii) SEQ ID NO: 83 and SEQ ID NO: 90, respectively;

(viii) SEQ ID NO: 91 and SEQ ID NO: 98, respectively;

(ix) SEQ ID NO: 99 and SEQ ID NO: 106, respectively;

(x) SEQ ID NO: 107 and SEQ ID NO: 114, respectively;

(xi) SEQ ID NO: 115 and SEQ ID NO: 122, respectively;

(xii) SEQ ID NO: 123 and SEQ ID NO: 130, respectively;

(xiii) SEQ ID NO: 131 and SEQ ID NO: 138, respectively;

(xiv) SEQ ID NO: 139 and SEQ ID NO: 146, respectively; and

(xv) SEQ ID NO: 147 and SEQ ID NO: 154, respectively.

87 . The nucleic acid of claim 75 , wherein:

the heavy chain CH1-CH2-CH3 sequence of SEQ ID NO: 155 or SEQ ID NO: 189 comprises:

a lysine to cysteine substitution at amino acid position 105 and deletion of a threonine at amino acid positions 106 and 108; and

a methionine to leucine substitution at amino acid position 311 and an asparagine to serine substitution at amino acid position 317; and

the light chain C L sequence of SEQ ID NO: 157 comprises a valine to cysteine substitution at amino acid position 98.

88 . The nucleic acid of claim 87 , wherein the antibody comprises heavy chain and light chain sequences selected from the group of:

(i) SEQ ID NO: 36 and SEQ ID NO: 42, respectively;

(ii) SEQ ID NO: 44 and SEQ ID NO: 50, respectively;

(iii) SEQ ID NO: 52 and SEQ ID NO: 58, respectively;

(iv) SEQ ID NO: 60 and SEQ ID NO: 66, respectively;

(v) SEQ ID NO: 68 and SEQ ID NO: 74, respectively;

(vi) SEQ ID NO: 76 and SEQ ID NO: 82, respectively;

(vii) SEQ ID NO: 84 and SEQ ID NO: 90, respectively;

(viii) SEQ ID NO: 92 and SEQ ID NO: 98, respectively;

(ix) SEQ ID NO: 100 and SEQ ID NO: 106, respectively;

(x) SEQ ID NO: 108 and SEQ ID NO: 114, respectively;

(xi) SEQ ID NO: 116 and SEQ ID NO: 122, respectively;

(xii) SEQ ID NO: 124 and SEQ ID NO: 130, respectively;

(xiii) SEQ ID NO: 132 and SEQ ID NO: 138, respectively;

(xiv) SEQ ID NO: 140 and SEQ ID NO: 146, respectively; and

(xv) SEQ ID NO: 148 and SEQ ID NO: 154, respectively.

89 . The nucleic acid of claim 75 , wherein:

the heavy chain CH1-CH2-CH3 sequence of SEQ ID NO: 155 or SEQ ID NO: 189 comprises:

a lysine to cysteine substitution at amino acid position 105 and deletion of a threonine at amino acid positions 106 and 108; and

the light chain C L sequence of SEQ ID NO: 157 comprises a valine to cysteine substitution at amino acid position 98.

90 . The nucleic acid of claim 89 , wherein the antibody comprises heavy chain and light chain sequences selected from the group of:

(i) SEQ ID NO: 37 and SEQ ID NO: 42, respectively;

(ii) SEQ ID NO: 45 and SEQ ID NO: 50, respectively;

(iii) SEQ ID NO: 53 and SEQ ID NO: 58, respectively;

(iv) SEQ ID NO: 61 and SEQ ID NO: 66, respectively;

(v) SEQ ID NO: 69 and SEQ ID NO: 74, respectively;

(vi) SEQ ID NO: 77 and SEQ ID NO: 82, respectively;

(vii) SEQ ID NO: 85 and SEQ ID NO: 90, respectively;

(viii) SEQ ID NO: 93 and SEQ ID NO: 98, respectively;

(ix) SEQ ID NO: 101 and SEQ ID NO: 106, respectively;

(x) SEQ ID NO: 109 and SEQ ID NO: 114, respectively;

(xi) SEQ ID NO: 117 and SEQ ID NO: 122, respectively;

(xii) SEQ ID NO: 125 and SEQ ID NO: 130, respectively;

(xiii) SEQ ID NO: 133 and SEQ ID NO: 138, respectively;

(xiv) SEQ ID NO: 141 and SEQ ID NO: 146, respectively; and

(xv) SEQ ID NO: 149 and SEQ ID NO: 154, respectively.

91 . The nucleic acid of claim 75 , wherein the heavy chain CH1-CH2-CH3 sequence of SEQ ID NO: 155 or SEQ ID NO: 189 comprises:

amino acid a lysine to cysteine substitution at amino acid position 105 and deletion of a threonine at positions 106 and 108; and

an alanine to a cysteine substitution at amino acid position 1.

92 . The nucleic acid of claim 91 , wherein the antibody comprises heavy chain and light chain sequences selected from the group of:

(i) SEQ ID NO: 38 and SEQ ID NO: 41, respectively;

(ii) SEQ ID NO: 46 and SEQ ID NO: 49, respectively;

(iii) SEQ ID NO: 54 and SEQ ID NO: 57, respectively;

(iv) SEQ ID NO: 62 and SEQ ID NO: 65, respectively;

(v) SEQ ID NO: 70 and SEQ ID NO: 73, respectively;

(vi) SEQ ID NO: 78 and SEQ ID NO: 81, respectively;

(vii) SEQ ID NO: 86 and SEQ ID NO: 89, respectively;

(viii) SEQ ID NO: 94 and SEQ ID NO: 97, respectively;

(ix) SEQ ID NO: 102 and SEQ ID NO: 105, respectively;

(x) SEQ ID NO: 110 and SEQ ID NO: 113, respectively;

(xi) SEQ ID NO: 118 and SEQ ID NO: 121, respectively;

(xii) SEQ ID NO: 126 and SEQ ID NO: 129, respectively;

(xiii) SEQ ID NO: 134 and SEQ ID NO: 137, respectively;

(xiv) SEQ ID NO: 142 and SEQ ID NO: 145, respectively; or

(xv) SEQ ID NO: 150 and SEQ ID NO: 153, respectively.

93 . The nucleic acid of claim 75 , wherein the heavy chain CH1-CH2-CH3 sequence of SEQ ID NO: 155 or SEQ ID NO: 189 comprises:

a lysine to cysteine substitution at amino acid position 105 and deletion of a threonine at amino acid positions 106 and 108;

a methionine to leucine substitution at amino acid position 311 and an asparagine to serine substitution at amino acid position 317; and

an alanine to a cysteine substitution at amino acid position 1.

94 . The nucleic acid of claim 93 , wherein the antibody comprises a heavy chain and a light chain sequence selected from the group of:

(i) SEQ ID NO: 39 and SEQ ID NO: 41, respectively;

(ii) SEQ ID NO: 47 and SEQ ID NO: 49, respectively;

(iii) SEQ ID NO: 55 and SEQ ID NO: 57, respectively;

(iv) SEQ ID NO: 63 and SEQ ID NO: 65, respectively;

(v) SEQ ID NO: 71 and SEQ ID NO: 73, respectively;

(vi) SEQ ID NO: 79 and SEQ ID NO: 81, respectively;

(vii) SEQ ID NO: 87 and SEQ ID NO: 89, respectively;

(viii) SEQ ID NO: 95 and SEQ ID NO: 97, respectively;

(ix) SEQ ID NO: 103 and SEQ ID NO: 105, respectively;

(x) SEQ ID NO: 111 and SEQ ID NO: 113, respectively;

(xi) SEQ ID NO: 119 and SEQ ID NO: 121, respectively;

(xii) SEQ ID NO: 127 and SEQ ID NO: 129, respectively;

(xiii) SEQ ID NO: 135 and SEQ ID NO: 137, respectively;

(xiv) SEQ ID NO: 143 and SEQ ID NO: 145, respectively; or

(xv) SEQ ID NO: 151 and SEQ ID NO: 153, respectively.

95 . The nucleic acid of claim 75 , wherein the heavy chain CH1-CH2-CH3 sequence of SEQ ID NO: 155 or SEQ ID NO: 189 comprises:

a lysine to cysteine substitution at amino acid position 105 and deletion of a threonine at amino acid positions 106 and 108;

an alanine to a cysteine substitution at amino acid position 1.

96 . The nucleic acid of claim 95 , wherein the antibody comprises a heavy chain and a light chain sequence selected from the group of:

(i) SEQ ID NO: 40 and SEQ ID NO: 41, respectively;

(ii) SEQ ID NO: 48 and SEQ ID NO: 49, respectively;

(iii) SEQ ID NO: 56 and SEQ ID NO: 57, respectively;

(iv) SEQ ID NO: 64 and SEQ ID NO: 65, respectively;

(v) SEQ ID NO: 72 and SEQ ID NO: 73, respectively;

(vi) SEQ ID NO: 80 and SEQ ID NO: 81, respectively;

(vii) SEQ ID NO: 88 and SEQ ID NO: 89, respectively;

(viii) SEQ ID NO: 96 and SEQ ID NO: 97, respectively;

(ix) SEQ ID NO: 104 and SEQ ID NO: 105, respectively;

(x) SEQ ID NO: 112 and SEQ ID NO: 113, respectively;

(xi) SEQ ID NO: 120 and SEQ ID NO: 121, respectively;

(xii) SEQ ID NO: 128 and SEQ ID NO: 129, respectively;

(xiii) SEQ ID NO: 136 and SEQ ID NO: 137, respectively;

(xiv) SEQ ID NO: 144 and SEQ ID NO: 145, respectively; or

(xv) SEQ ID NO: 152 and SEQ ID NO: 153, respectively.

97 . An expression vector that comprises the nucleic acid comprising the sequences encoding the antibody of claim 75 .

98 . A recombinant cell comprising the expression vector of claim 97 .

99 . A method of producing the antibody, wherein the method comprises:

introducing into a cell the expression vector of claim 97 ; and

culturing the cell under conditions sufficient for the expression of the antibody.

100 . A pair of expression vectors that together comprise the nucleic acid comprising the sequences encoding the antibody of claim 75 .

101 . A recombinant cell comprising the pair of expression vectors of claim 100 .

102 . A method of producing the antibody, wherein the method comprises:

introducing into a cell the pair of expression vectors of claim 100 ; and

culturing the cell under conditions sufficient for the expression of the antibody.

Assignments (3)

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 1, 2026

From: MYTHIC THERAPEUTICS, INC.

To: MYTHIC ABC, LLC

Reel/Frame 075155/0119 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 1, 2026

From: MYTHIC ABC, LLC

To: GILEAD SCIENCES, INC.

Reel/Frame 075155/0157 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 25, 2023

From: FISKE, BRIAN P.; GERA, NIMISH; NICHOLS, ALEXANDER J.

To: MYTHIC THERAPEUTICS, INC.

Reel/Frame 064372/0662 →